01:31 , Mar 15, 2019 |  BC Innovations  |  Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
17:05 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers A three-protein signature in tumor-infiltrating lymphocytes (TILs) could help predict response to PD-1 and PD-L1 inhibitors in NSCLC. In pre-treatment tumor samples from 39 NSCLC patients treated with PD-1 or PD-L1 inhibitors,...
19:30 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

MEI's ME-344 inhibits tumor cell proliferation in breast cancer trial

MEI Pharma Inc. (NASDAQ:MEIP) said ME-344 plus Avastin bevacizumab led to greater inhibition of tumor cell proliferation compared with placebo plus Avastin as measured by the mean reduction in antigen KI-67 (MKI67; Ki-67) expression in...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

Intraductal fulvestrant: Phase II started

Atossa began the open-label, U.S. Phase II 007 trial to compare intraductal fulvestrant delivered via its microcatheter device vs. intramuscular Faslodex fulvestrant in about 30 patients who are scheduled to undergo a mastectomy. Faslodex is...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

KTN3379: Phase I started

Kolltan began an open-label, U.S. Phase I trial to evaluate KTN3379 prior to surgical resection of tumor in about 29 HPV-negative and HPV-positive patients with SCCHN. Kolltan Pharmaceuticals Inc. , New Haven, Conn.   Product:...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

BioNTech sales and marketing update

BioNTech launched its CE-IVD MammaTyper test to stratify breast cancer patients by molecular subtype. The in vitro test based on RT-qPCR technology detects mRNA expression levels of the biomarkers estrogen receptor 1 ( ESR1 ),...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Rosetta Genomics sales and marketing update

Rosetta launched two fibroblast growth factor (FGF) receptor 3 ( FGFR3 ; CD333 ) gene mutation assays. The first detects the recurrence of FGFR3-positive low-grade bladder cancer from urine. The second, in conjunction with antigen...
07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: CD4+ T cell markers of active tuberculosis for diagnosis and monitoring treatment responses

Biomarkers TECHNOLOGY: Plasma markers Markers of immune activation on Mycobacterium tuberculosis-specific T cells could help diagnose active tuberculosis and monitor treatment responses. In blood from a cohort of patients whose tuberculosis was diagnosed by sputum...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Roche sales and marketing update

Roche launched the automated CINtec PLUS cytology test in Europe, Asia, Latin America and Canada to detect pre-cancerous cervical disease. The test helps identify women with high-grade pre-cancerous cervical lesions who need immediate colposcopy. In...
07:00 , Jul 12, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Genomic markers to guide the use of neoadjuvant aromatase inhibitors in patients with breast cancer Whole-genome and exome sequencing of pretreatment tumor biopsies from patients with...